enfuvirtid first hiv fusion inhibitor approve treatment vivid patient fail respond current antiretrovir drug howe clinic applied limit short halflif drug resist crossreact preexist antibody hivinfect use artificial peptide strategy design non protein sequence ap exhibit potent antivirus active broad spectrum strain include resist remark longer vivo significantly suppress t neither recon attend antihiv structure differ could fold singlehelix interact gp hr two reside met thr terminus form hooklik structure static interact helix therefore potent develop new improv efficacy profil pharmacology property meanwhile studi highlight advantage artificial peptide confirm use develop peptides viral inhibitor envelope virus 